119 results
Page 2 of 6
425
EX-99.1
dv4uv58mnaquqve
15 May 23
Business combination disclosure
4:06pm
8-K
EX-99.1
e1ur3r2 1nzpu
15 May 23
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
S-4
EX-10.9
b6gv5wus3873rfh
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
pxx7xd1v 9gedlylr1
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.11
99oeudi2
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.3
3obb4s5q0eybf0 cooog
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.1
c0cz6y33q r9
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.2
4ecdltyd lt16
14 Nov 22
VBL Therapeutics Reports Third Quarter 2022 Financial Results
4:19pm
6-K
EX-99.1
0lgjr492
1 Sep 22
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
5:16pm
6-K
EX-99.3
yxyxi5zp5 ecq0x
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.1
pdk3kj wn5
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.2
87of7rnzhipo cq9u2bf
15 Aug 22
VBL Therapeutics Announces Second Quarter 2022 Financial Results
4:07pm
6-K
EX-99.1
pprznxq1w5ndk5lc3c3
2 Aug 22
VBL Therapeutics Announces Workforce Reduction
8:32am
6-K
EX-99.1
v1xm9ev4d 5rndx
19 Jul 22
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
4:09pm
6-K
EX-99.2
ryitgnxoaau 4m928q
2 Jun 22
Notice of Annual General Meeting of Shareholders
5:00pm
6-K
EX-99.2
leplu31 aid2qfj
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-99.3
cqf32wy
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-99.1
uorj6
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-99.1
t75j5zf1i guima
26 Apr 22
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
8:05am
6-K
EX-99.1
afj9jd6hvnot 5il
23 Mar 22
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
7:33am